News | February 19, 2026
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
Subscribe To Our Newsletter & Stay Updated
